Working on Wellness: A Capacity Building Program for Massachusetts Employers

In recent years, more worksites have shown an interest in offering wellness programs to their employees. However, uptake of worksite wellness programs remains low among certain employer groups, such as small businesses and employers in low wage industries. This poster will highlight the Working on Wellness (WoW) program; an innovative \u27capacity building\u27 program designed to help employers across the state implement evidence-based worksite initiatives and policies that foster a healthier work environment. Through a collaborative partnership with the MA Department of Public Health, a public health institute, a cadre of worksite wellness experts, and university researchers, over 150 businesses were recruited to participate in WoW this past year. This poster will describe WoW\u27s innovative framework, the tools and resources available to businesses (e.g., seed funding, community connections and collaboration, access to a comprehensive online curriculum, and technical assistance), and examine program strengths and weaknesses. The methods used in this model to teach the concepts and skills of building a worksite wellness program will be examined. The evaluation aspects of the program, undertaken by UMass Medical and UMass Lowell will be identified. Lastly, the poster will feature case studies of participating organizations, highlighting the interventions implemented in their worksites to impact employee health. This poster is one of a series of posters on this project presented by the project team: UMass Medical, UMass Lowell, Health Resources in Action and AdvancingWellness

Working on Wellness: Building Capacity through Community Partnerships

Establishing a wellness initiative in the workplace is a popular way for employers to attract and retain top talent, reduce health costs, and increase productivity. However, building a comprehensive wellness initiative can put a strain on an organization\u27s time and resources. Working on Wellness (WoW) is an innovative \u27capacity building\u27 program designed to help employers across Massachusetts implement evidence-based worksite initiatives and policies that foster a healthier work environment. To broaden the understanding among employers about what influences health, WoW\u27s Community Partnerships component introduces organizations to the notion that businesses can play a key role in building healthy communities. The curriculum describes how employers can join efforts to improve the places where they live, work and play. Businesses are encouraged to incorporate interventions into their worksite wellness programs and policies that show mutually beneficial outcomes between employers and community partners. This poster will introduce tools and resources created through WoW including our approach to introduce community partnerships through our online training modules and our Community Scan assessment tool, which provides a roadmap to consider traditional and nontraditional partners for organization\u27s wellness interventions. The poster will feature case studies highlighting how participants used the Community Scan to find and establish strong partnerships to reach their goals of increasing fruit and vegetable consumption, reducing stress, and increasing physical activity among employees and community residents. This poster is one of a series of posters on this project presented by the project team: UMass Medical, UMass Lowell, Health Resources in Action and AdvancingWellness

The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging: Methodology and Baseline Characteristics of 1112 Individuals Recruited for a Longitudinal Study of Alzheimer\u27s Disease

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer\u27s disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants. Methods: Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning. Results: A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring. Conclusion: The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline

Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)

Pyridoxine-dependent epilepsy was recently shown to be due to mutations in the ALDH7A1 gene, which encodes antiquitin, an enzyme that catalyses the nicotinamide adenine dinucleotide-dependent dehydrogenation of L-{alpha}-aminoadipic semialdehyde/L-{Delta}1-piperideine 6-carboxylate. However, whilst this is a highly treatable disorder, there is general uncertainty about when to consider this diagnosis and how to test for it. This study aimed to evaluate the use of measurement of urine L-{alpha}-aminoadipic semialdehyde/creatinine ratio and mutation analysis of ALDH7A1 (antiquitin) in investigation of patients with suspected or clinically proven pyridoxine-dependent epilepsy and to characterize further the phenotypic spectrum of antiquitin deficiency. Urinary L-{alpha}-aminoadipic semialdehyde concentration was determined by liquid chromatography tandem mass spectrometry. When this was above the normal range, DNA sequencing of the ALDH7A1 gene was performed. Clinicians were asked to complete questionnaires on clinical, biochemical, magnetic resonance imaging and electroencephalography features of patients. The clinical spectrum of antiquitin deficiency extended from ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to the onset of seizures and autistic features after the first year of life. Our relatively large series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because: (i) there may be some response to antiepileptic drugs; (ii) in infants with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) structural brain abnormalities may co-exist and be considered sufficient cause of epilepsy, whereas the fits may be a consequence of antiquitin deficiency and are then responsive to pyridoxine. These findings support the use of biochemical and DNA tests for antiquitin deficiency and a clinical trial of pyridoxine in infants and children with epilepsy across a broad range of clinical scenarios

Spillway-Induced Salmon Head Injury Triggers the Generation of Brain αII-Spectrin Breakdown Product Biomarkers Similar to Mammalian Traumatic Brain Injury

Recent advances in biomedical research have resulted in the development of specific biomarkers for diagnostic testing of disease condition or physiological risk. Of specific interest are αII-spectrin breakdown products (SBDPs), which are produced by proteolytic events in traumatic brain injury and have been used as biomarkers to predict the severity of injury in humans and other mammalian brain injury models. This study describes and demonstrates the successful use of antibody-based mammalian SBDP biomarkers to detect head injury in migrating juvenile Chinook salmon (Oncorhynchus tshawytscha) that have been injured during passage through high-energy hydraulic environments present in spillways under different operational configurations. Mortality and injury assessment techniques currently measure only near-term direct mortality and easily observable acute injury. Injury-based biomarkers may serve as a quantitative indicator of subacute physical injury and recovery, and aid hydropower operators in evaluation of safest passage configuration and operation actions for migrating juvenile salmonids. We describe a novel application of SBDP biomarkers for head injury for migrating salmon. To our knowledge, this is the first documented cross-over use of a human molecular biomarker in a wildlife and operational risk management scenario

Bioarchaeological approaches to understanding the long-term development of mountain societies

Archaeologists do not always differentiate between human activities, practices and techniques within landscape archaeology. This problem is reflected in some research into the development of pastoralism in the Alps. Here, we develop a framework within a “position paper” that engages with these different processes by assessing recent developments in bioarchaeological and palaeoenvironmental methods. Over the last two decades, alpine research has moved beyond the mere characterisation of human activities toward the classification and interpretation of specific practices and techniques, changing how we study the development of alpine pastoralism. Research into the development of mid-/long-distance transhumance from the Provencal plains to the Western Alps has generated considerable interest over the last 20 years. Therefore, the PATHWAy (Pastoralism, TransHumance in the Western Alps) project focuses on studying the Iron Age to Medieval pastoral systems in the Western Alps and south-eastern France, which is today one of the main regions in Europe where transhumant pastoralism still takes place. Finally, this contribution aims to review how bioarchaeological methods, combined with “cultural” archaeology, inform detailed quotidian aspects of lifeways rather than impactful, mediatised generalising statements, such as mass population movements or simplistic generalisations about past diet

Genomic surveillance of Escherichia coli and Klebsiella spp. in hospital sink drains and patients

Escherichia coli and Klebsiella spp. are important human pathogens that cause a wide spectrum of clinical disease. In healthcare settings, sinks and other wastewater sites have been shown to be reservoirs of antimicrobial-resistant E. coli and Klebsiella spp., particularly in the context of outbreaks of resistant strains amongst patients. Without focusing exclusively on resistance markers or a clinical outbreak, we demonstrate that many hospital sink drains are abundantly and persistently colonised with diverse populations of E. coli, Klebsiella pneumoniae and Klebsiella oxytoca, including both antimicrobial-resistant and susceptible strains. Using whole genome sequencing (WGS) of 439 isolates, we show that environmental bacterial populations are largely structured by ward and sink, with only a handful of lineages, such as E. coli ST635, being widely distributed, suggesting different prevailing ecologies which may vary as a result of different inputs and selection pressures. WGS of 46 contemporaneous patient isolates identified one (2%; 95% CI 0.05-11%) E. coli urine infection-associated isolate with high similarity to a prior sink isolate, suggesting that sinks may contribute to up to 10% of infections caused by these organisms in patients on the ward over the same timeframe. Using metagenomics from 20 sink-timepoints, we show that sinks also harbour many clinically relevant antimicrobial resistance genes including blaCTX-M, blaSHV and mcr, and may act as niches for the exchange and amplification of these genes. Our study reinforces the potential role of sinks in contributing to Enterobacterales infection and antimicrobial resistance in hospital patients, something that could be amenable to intervention

Environmental and Parental Influences on Offspring Health and Growth in Great Tits (Parus major)

PMCID: PMC3728352This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)

Pyridoxine-dependent epilepsy was recently shown to be due to mutations in the ALDH7A1 gene, which encodes antiquitin, an enzyme that catalyses the nicotinamide adenine dinucleotide-dependent dehydrogenation of l-α-aminoadipic semialdehyde/l-Δ1-piperideine 6-carboxylate. However, whilst this is a highly treatable disorder, there is general uncertainty about when to consider this diagnosis and how to test for it. This study aimed to evaluate the use of measurement of urine l-α-aminoadipic semialdehyde/creatinine ratio and mutation analysis of ALDH7A1 (antiquitin) in investigation of patients with suspected or clinically proven pyridoxine-dependent epilepsy and to characterize further the phenotypic spectrum of antiquitin deficiency. Urinary l-α-aminoadipic semialdehyde concentration was determined by liquid chromatography tandem mass spectrometry. When this was above the normal range, DNA sequencing of the ALDH7A1 gene was performed. Clinicians were asked to complete questionnaires on clinical, biochemical, magnetic resonance imaging and electroencephalography features of patients. The clinical spectrum of antiquitin deficiency extended from ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to the onset of seizures and autistic features after the first year of life. Our relatively large series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because: (i) there may be some response to antiepileptic drugs; (ii) in infants with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) structural brain abnormalities may co-exist and be considered sufficient cause of epilepsy, whereas the fits may be a consequence of antiquitin deficiency and are then responsive to pyridoxine. These findings support the use of biochemical and DNA tests for antiquitin deficiency and a clinical trial of pyridoxine in infants and children with epilepsy across a broad range of clinical scenario